Nimodipina Tecnilor (Nimodipine)

Nimodipine selectively antagonizes L‑type voltage‑gated calcium channels on vascular smooth‑muscle cells, especially within cerebral arteries. This inhibition reduces calcium influx, leading to vasodilation, improved cerebral perfusion, and neuroprotective effects while also contributing to systemic blood‑pressure reduction.

The dosage of Nimodipina Tecnilor is determined by the prescribing clinician based on the specific indication, patient characteristics, and local treatment guidelines. Healthcare professionals set the appropriate regimen after evaluating the individual’s clinical needs.

Safety data for nimodipine in pregnancy and lactation are limited. It is generally avoided unless the potential therapeutic benefit justifies the possible risk to the fetus or infant. Patients should discuss any concerns with their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimodipine is distinguished by its high selectivity for cerebral vessels, offering superior neurovascular protection compared with less brain‑focused agents such as nicardipine or amlodipine. While all belong to the dihydropyridine class, nimodipine’s pharmacokinetic profile and lipophilicity make it especially effective for preventing cerebral vasospasm.

Store Nimodipina Tecnilor at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Nimodipina Tecnilor is taken orally. The tablet (or capsule) should be swallowed whole with a glass of water. It may be administered with or without food, following the prescribing information provided by the treating physician.

The most serious adverse events include severe hypotension, myocardial infarction or other cardiac ischemic events, hepatic dysfunction, severe allergic reactions such as anaphylaxis, and rare blood disorders like neutropenia or thrombocytopenia. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to nimodipine or any excipients, those experiencing severe hypotension, individuals with certain cardiac conduction abnormalities, and patients taking contraindicated drug combinations should avoid this medication. Clinical judgment is essential to identify any additional contraindications.